Thoma spent the first part of her career at BASF in New Jersey, USA, where she rose to leadership positions in the pharmaceutical ingredients business
Nanoform, a nanoparticle medicine enabling company, will elect Jeanne Thoma as a board member during a general meeting on November 17.
Thoma spent the first part of her career at BASF in New Jersey, USA, where she rose to leadership positions in the pharmaceutical ingredients business, including within sales, marketing, manufacturing operations, and supply chain. She holds dual US and Irish citizenship.
Today Thoma serves as independent director on the boards of ANI Pharmaceuticals, Avid Bioservices and Vectura Group Jeanne has served two four-year terms on the board of directors for DCAT (Drug, Chemical & Associated Technologies Association, Inc.) and she currently serves as a member of the board of advisors to DCAT.
Electing Thoma to the board of directors of Nanoform is subject to the decision made at Nanoform’s EGM on November 17, 2021.
Prof Edward Hæggström, Nanoform CEO, said: “Following the successful completion of our clinical trial and commercial expansion, we’ve reached an exciting point in Nanoform’s growth trajectory and are delighted to welcome Ms. Thoma as a new board member during this busy time. Her remarkable career speaks for itself, and her insights will be invaluable as we continue on our mission to touch the lives of a billion patients worldwide through our game-changing nanoforming technologies.”
Jeanne Thoma commented: “Patients stand to benefit greatly from increased uptake of technological innovations in pharma. In my role as board member, I look forward to being a part of Nanoform’s journey, developing life-changing therapeutics and transforming patients’ lives by continuing to expand the reach of its unique nanoforming technologies.”